JP2009532369A - 分泌性白血球プロテアーゼインヒビターによる神経再生の刺激 - Google Patents

分泌性白血球プロテアーゼインヒビターによる神経再生の刺激 Download PDF

Info

Publication number
JP2009532369A
JP2009532369A JP2009503084A JP2009503084A JP2009532369A JP 2009532369 A JP2009532369 A JP 2009532369A JP 2009503084 A JP2009503084 A JP 2009503084A JP 2009503084 A JP2009503084 A JP 2009503084A JP 2009532369 A JP2009532369 A JP 2009532369A
Authority
JP
Japan
Prior art keywords
slpi
neuron
disease
neurons
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532369A5 (https=
Inventor
マリー ティー． フィルビン，
サリー エス． ハニラ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of City University of New York
Original Assignee
Research Foundation of City University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of City University of New York filed Critical Research Foundation of City University of New York
Publication of JP2009532369A publication Critical patent/JP2009532369A/ja
Publication of JP2009532369A5 publication Critical patent/JP2009532369A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009503084A 2006-03-30 2007-03-30 分泌性白血球プロテアーゼインヒビターによる神経再生の刺激 Pending JP2009532369A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78802106P 2006-03-30 2006-03-30
US78792706P 2006-03-31 2006-03-31
PCT/US2007/008270 WO2007117440A2 (en) 2006-03-30 2007-03-30 Stimulation of neuron regeneration by secretory leukocyte protease inhibitor

Publications (2)

Publication Number Publication Date
JP2009532369A true JP2009532369A (ja) 2009-09-10
JP2009532369A5 JP2009532369A5 (https=) 2010-05-20

Family

ID=38542264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503084A Pending JP2009532369A (ja) 2006-03-30 2007-03-30 分泌性白血球プロテアーゼインヒビターによる神経再生の刺激

Country Status (5)

Country Link
US (1) US8367615B2 (https=)
EP (1) EP2012819A2 (https=)
JP (1) JP2009532369A (https=)
CA (1) CA2647246C (https=)
WO (1) WO2007117440A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528913A (ja) * 2011-06-28 2014-10-30 インヒブルクス リミティド ライアビリティ カンパニー Ｗａｐドメイン融合ポリペプチド及びその使用方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN110551223A (zh) 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537970A (ja) * 2000-12-18 2004-12-24 アライバ ファーマシューティカルズ，インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
CA2187626C (en) * 1994-04-13 2009-11-03 Michael G. Kaplitt Aav-mediated delivery of dna to cells of the nervous system
US6096716A (en) * 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
ATE275415T1 (de) * 1995-06-27 2004-09-15 Res Foundation Of Cuny Hunter Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
CA2247912A1 (en) 1996-03-04 1997-09-12 University Of Medicine & Dentistry Of New Jersey Genetically engineered primary oligodendrocytes for transplantation-mediated gene delivery in the central nervous system
US6210664B1 (en) * 1996-04-08 2001-04-03 New York University Medical Center Method for gene transfer to the central nervous system
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
GB9816775D0 (en) 1998-07-31 1998-09-30 Efstathiou Stacey Herpesviral vectors for gene delivery
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
DE60137414D1 (de) 2000-05-05 2009-03-05 Univ City Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
US20020168760A1 (en) * 2001-03-13 2002-11-14 Dornburg Ralph C. Retroviral vectors for gene transfer into neuronal cells
WO2006028586A2 (en) * 2004-07-22 2006-03-16 Duke University Biomarkers and therapeutic targets for cognitive decline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537970A (ja) * 2000-12-18 2004-12-24 アライバ ファーマシューティカルズ，インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012028369; Ｍｏｌｅｃｕｌａｒ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．６４，　Ｎｏ．４, 2003, ｐ．８３３-８４０ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528913A (ja) * 2011-06-28 2014-10-30 インヒブルクス リミティド ライアビリティ カンパニー Ｗａｐドメイン融合ポリペプチド及びその使用方法

Also Published As

Publication number Publication date
US20100256065A1 (en) 2010-10-07
CA2647246C (en) 2015-06-23
WO2007117440A2 (en) 2007-10-18
WO2007117440A3 (en) 2008-04-17
US8367615B2 (en) 2013-02-05
EP2012819A2 (en) 2009-01-14
CA2647246A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
JP7503590B2 (ja) 遺伝子構築物
JP6203215B2 (ja) プロミニン−１ペプチド断片およびその使用
JP6920324B2 (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
RU2757932C2 (ru) Генетическая конструкция для применения при лечении нейродегенеративного нарушения или инсульта
KR20240025721A (ko) 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
US20170029798A1 (en) Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
US20110262432A1 (en) mutated netrin 4 proteins, fragments thereof and their uses as drugs
JP2020518261A (ja) Ｃ末端ｃｄｎｆ断片及びｃ末端ｍａｎｆ断片、それらを含む医薬組成物、並びにそれらの使用
JP5231214B2 (ja) エリスロポエチン変異体
KR20230159847A (ko) 염증성 또는 활성화된 세포를 표적으로 하고 염증성 상태 및 통증을 치료 또는 개선하기 위한 조성물 및 방법
US8956622B2 (en) Peptidic antagonists of class III semaphorins/neuropilins complexes
US8367615B2 (en) Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
WO2001085981A2 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
AU2001259453A1 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
EP1900374B1 (en) Angiogenetic agent containing adrenomedulin as the active ingredient
JP2000501416A (ja) ニューロン病を治療し予防するための、治療法および薬物のスクリーニング法
KR102772298B1 (ko) 미엘린 장애의 치료를 위한 조성물 및 방법
US8163700B2 (en) Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
US20060153884A1 (en) Peptide fragments of the harp factor inhibiting angiogenesis
US20250263456A1 (en) Use of fgf5 transcript variant-2 and protein thereof in preventing, inhibiting, or treating liver fibrosis
KR20120087410A (ko) Ｎｅｌｌ2를 유효성분으로 포함하는 소포체 스트레스 관련 질환의 예방 또는 치료용 조성물
Shahsavani Evaluating the role of Neuregulin-1β1 in neuroprotection after spinal cord injury
US20130171139A1 (en) Ncam-vase and neurodegeneration
JP2007284410A (ja) 神経新生促進剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121106